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BIS -QUATERNARY AMMONIUM 
CYCLOPHANE COMPOUNDS THAT 
INTERACT WITH NEURONAL NICOTINIC 
ACETYLCHOLINE RECEPTORS 
CONTINUING APPLICATION DATA 
This application is a national stage of PCT/US2007/ 
011269, ?led May 11, 2007, Which claims bene?t of US. 
Provisional Application No. 60/799,881, ?led May 12, 2006, 
Which is incorporated herein by reference in its entirety. 
IDENTIFICATION OF FEDERAL FUNDING 
The present invention Was supported by Grant NIH 
U19DA017548 from the National Institutes of Health, and 
therefore the government may have rights in the invention. 
FIELD OF THE INVENTION 
The invention relates to bis-quatemary ammonium cyclo 
phane compounds that interact With neuronal nicotinic recep 
tors, and to methods of using the compounds to treat central 
nervous system diseases and pathologies. 
BACKGROUND OF THE INVENTION 
S(—)-Nicotine (NIC) activates presynaptic and postsynap 
tic neuronal nicotinic receptors that evoke the release of neu 
rotransmitters from presynaptic terminals and that modulate 
the depolariZation state of the postsynaptic neuronal mem 
brane, respectively. Thus, nicotine produces its effect by 
binding to a family of ligand-gated ion channels, stimulated 
by acetylcholine (ACh) or nicotine Which causes the ion 
channel to open and cations to ?ux With a resulting rapid 
(millisecond) depolarization of the target cell. 
Neuronal nicotinic receptors are composed of tWo types of 
subunits, 0t and [3, and assemble as heteromeric receptors With 
the general stoichiometry of 2a and 3[3 or as homomeric 
receptors With 5a subunits. Nine subtypes of the ot subunit 
(a2 to (x10) and three subtypes of the [3 unit ([32 to [34) are 
found in the central nervous system. The mo st common nico 
tinic receptor subtype in the brain is composed of tWo (X4 and 
three [32 subunits, i.e., (X462. These subunits display different, 
but overlapping, patterns of expression in the brain. Examples 
of heteromeric receptor subtypes include (X462, (X362, (X3 [34, 
(X662, (x6[32[33, (x40t5[32, (x60t5[32, (x60t4[32, (x60t4[32[33, 
(x4[32[34, (X3 [32[34, and others. The predominant homomeric 
subtype includes (x7, but other combinations have also been 
proposed. 
For the most part, the actual subunit compositions and 
stoichiometries of nicotinic receptors in the brain remain to 
be elucidated. Thus, neuronal nicotinic receptor subtype 
diversity originates from differences in the amino acid 
sequence at the subunit level and from the multiple combina 
tions of assemblies of subunits into functional receptor pro 
teins, Which affords a Wide diversity of pharmacological 
speci?city. 
In spite of the extensive diversity in neuronal nicotinic 
receptor messenger RNA expression, only a limited number 
of tools are available to study the pharmacology of native 
receptors. Radioligands are used in many studies. [3H]NIC 
appears to label the same sites in the brain as [3H]ACh. It has 
been estimated that over 90% of [3H]NIC binding in the brain 
is due to association With the heteromeric receptor that is 
composed of (X4 and [32 subunits. Also abundant in the central 
nervous system are the homomeric receptors labeled by [3 H] 
20 
25 
30 
35 
40 
45 
50 
55 
60 
65 
2 
methyllycaconitine (MLA), Which has high af?nity for the (X7 
nicotinic receptor subtype. Nicotinic receptor subtypes can 
be studied using functional assays, such as NIC-evoked neu 
rotransmitter release (e.g., [3H]dopamine (DA) release, [3 H] 
norepinephrine (NE) release, [3H]serotonin (5-HT) release, 
[3H]gamma-aminobutyric acid (GABA) release and [3 H] 
glutamate release) from superfused rat brain slices. Nicotinic 
receptors are located in the cell body and terminal areas of 
these neurotransmitter systems. NIC facilitates neurotrans 
mitter release from nerve terminals. 
The structural and functional diversity of central nervous 
system nicotinic receptors has stimulated a great deal of inter 
est in developing novel, subtype-selective agonists and/or 
antagonists. Some of these agonists are currently being evalu 
ated in clinical trials for cognitive enhancement and neuro 
protective effects, potentially bene?cial for disease states 
such as AlZheimer’s and Parkinson’s disease, as Well as for 
treatment of drug abuse, depression, obesity and pain relief. 
SUMMARY OF THE INVENTION 
In one embodiment, compounds corresponding to the fol 
loWing structure are provided. 
(I) 
Q 
X16 and X26 are each independently an organic or inor 
ganic anion. 
Q and T are each independently attached to R1 and R2. Q 
and T are each independently selected from alkyl, substituted 
alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, substituted 
alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, 
alkylaryl, substituted alkylaryl, arylalkyl, substituted aryla 
lkyl, arylalkenyl, substituted arylalkenyl, arylalkynyl, substi 
tuted arylalkynyl, heterocyclic, substituted heterocyclic; 
SOYl, SOZYI, SOZOYl or SO2NHY1, where Y1 is selected 
from hydrogen, loWer alkyl, alkenyl, alkynyl or aryl, and 
where Y1 is not hydrogen in SOYl and if Y1 is alkenyl or 
alkynyl, the site of unsaturation is not conjugated With a 
heteroatom; COY2, Where Y2 is selected from hydrogen, 
alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, 
alkoxy, alkenyl, substituted alkenyl, alkynyl, substituted 
alkynyl, aryl, substituted aryl, aryloxy, alkylaryl, substituted 
alkylaryl, arylalkyl, substituted arylalkyl, arylalkenyl, substi 
tuted arylalkenyl, arylalkynyl, substituted arylalkynyl, het 
erocyclic, or substituted heterocyclic, and Where if Y2 com 
prises alkenyl or alkynyl, the site of unsaturation is not 
conjugated With the carbonyl group; 0Y3, Where Y3 is 
selected from hydrogen, alkyl, substituted alkyl, cycloalkyl, 
substituted cycloalkyl, alkenyl, substituted alkenyl, alkynyl, 
substituted alkynyl, aryl, substituted aryl, alkylaryl, substi 
tuted alkylaryl, arylalkyl, substituted arylalkyl, arylalkenyl, 
substituted arylalkenyl, arylalkynyl, substituted arylalkynyl, 
acyl, alkylsulfonyl, arylsulfonyl, heterocyclic, or substituted 
heterocyclic, Where if Y3 comprises alkenyl or alkynyl, the 
site of unsaturation is not conjugated With the oxygen; 
NY4Y5, Where Y4 and Y5 are each independently selected 
from hydrogen, alkyl, substituted alkyl, cycloalkyl, substi 
tuted cycloalkyl, alkenyl, substituted alkenyl, alkynyl, substi 
tuted alkynyl, aryl, substituted aryl, alkylaryl, substituted 
alkylaryl, arylalkyl, substituted arylalkyl, arylalkenyl, substi 
tuted arylalkenyl, arylalkynyl, substituted arylalkynyl, acyl, 
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alkylsulfonyl, arylsulfonyl, heterocyclic, or substituted het 
erocyclic, Where if Y4 orY5 comprises alkenyl or alkynyl, the 
site of unsaturation is not conjugated With the nitrogen; SY6, 
Where Y6 is selected from hydrogen, alkyl, substituted alkyl, 
cycloalkyl, substituted cycloalkyl, alkenyl, substituted alk 
enyl, alkynyl, substituted alkynyl, aryl, substituted aryl, alky 
laryl, substituted alkylaryl, arylalkyl, substituted arylalkyl, 
arylalkenyl, substituted arylalkenyl, arylalkynyl, substituted 
arylalkynyl, heterocyclic, or substituted heterocyclic, and 
Where if Y6 comprises alkenyl or alkynyl, the site of unsat 
uration is not conjugated With the sulfur. 
R1 and R2 are each independently ?ve or six membered 
rings as shoWn in formulas (HA) and (HE), Wherein each ring 
of R1 and R2 has one, tWo or three nitrogen atoms, each ring 
of R1 and R2 has one quaterniZed nitrogen, and tWo of R3 
through R24 of each R1 and tWo of R3 through R24 of each R2 
are replaced by one attachment to Q and one attachment to T. 
(IIA) 
(HE) 
A1 is carbon or nitrogen, provided that WhenAl joins a ring 
atom With an unsaturated bond or is a nitrogen, R3 is absent, 
and When A1 joins a ring atom With an unsaturated bond and 
is a nitrogen, both R3 and R4 are absent. 
A2 is carbon or nitrogen, provided that When A2 joins a ring 
atom With an unsaturated bond or is a nitrogen, R5 is absent, 
and When A2 joins a ring atom With an unsaturated bond and 
is a nitrogen, both R5 and R6 are absent. 
A3 is carbon or nitrogen, provided that When A3 joins a ring 
atom With an unsaturated bond or is a nitrogen, R7 is absent, 
and When A3 joins a ring atom With an unsaturated bond and 
is a nitrogen, both R7 and R8 are absent. 
A4 is carbon or nitrogen, provided that When A4 j oins a ring 
atom With an unsaturated bond or is a nitrogen, R9 is absent, 
and When A4 joins a ring atom With an unsaturated bond and 
is a nitrogen, both R9 and R10 are absent. 
A5 is carbon or nitrogen, provided that When A5 joins a ring 
atom With an unsaturated bond or is a nitrogen, R1 l is absent, 
and When A5 joins a ring atom With an unsaturated bond and 
is a nitrogen, both R11 and R12 are absent. 
A6 is carbon or nitrogen, provided that When A6 joins a ring 
atom With an unsaturated bond or is a nitrogen, R13 is absent, 
and When A6 joins a ring atom With an unsaturated bond and 
is a nitrogen, both R13 and R14 are absent. 
A7 is carbon or nitrogen, provided that When A7 joins a ring 
atom With an unsaturated bond or is a nitrogen, R15 is absent, 
and When A7 joins a ring atom With an unsaturated bond and 
is a nitrogen, both R15 and R16 are absent. 
A8 is carbon or nitrogen, provided that When A8 joins a ring 
atom With an unsaturated bond or is a nitrogen, R17 is absent, 
and When A8 joins a ring atom With an unsaturated bond and 
is a nitrogen, both R17 and R18 are absent. 
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A9 is carbon or nitrogen, provided that WhenA9 joins a ring 
atom With an unsaturated bond or is a nitrogen, R19 is absent, 
and When A9 joins a ring atom With an unsaturated bond and 
is a nitrogen, both R19 and R20 are absent. 
A10 is carbon or nitrogen, provided that When A10 joins a 
ring atom With an unsaturated bond or is a nitrogen, R21 is 
absent, and When A10 joins a ring atom With an unsaturated 
bond and is a nitrogen, both R21 and R22 are absent. 
All is carbon or nitrogen, provided that When All joins a 
ring atom With an unsaturated bond or is a nitrogen, R23 is 
absent, and When All joins a ring atom With an unsaturated 
bond and is a nitrogen, both R23 and R24 are absent. 
R3’ R4’ R5’ R6’ R7’ R8’ R9’ R10’ R11’ R12’ R13 and R14’ or 
R15’ R16’ R17’ R18’ R19’ R20’ R21’ R22’ R23 and R24’ When 
present, are each independently selected from hydrogen, 
alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, 
alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, 
aryl, substituted aryl, alkylaryl, substituted alkylaryl, aryla 
lkyl, substituted arylalkyl, arylalkenyl, substituted arylalk 
enyl, arylalkynyl, substituted arylalkynyl, heterocyclic, sub 
stituted heterocyclic, halo, cyano, nitro; or tWo adjacent 
groups R3 through R14, or groups R15 through R24, together 
With the atoms to Which they are attached on the ring of (HA) 
or (IIB) independently form a three to eight member cyclol 
kane, substituted cycloalkane, cycloalkene, substituted 
cycloalkene, aryl, substituted aryl, heterocycle With one to 
three hetero atoms of nitrogen, oxygen or sulfur in the ring, or 
substituted heterocycle With one to three hetero atoms of 
nitrogen, oxygen or sulfur in the ring; and When all of the 
bonds to the ring ammonium nitrogen are saturated, then any 
OfR3’ R4’ R5’ R6’ R7’ R8’ R9’ R10’ R11’ R12’ R13’ R14’ R15’ R16, 
R17, R18, R19, R20, R21, R22, R23 or R24 Which is attached to 
the ammonium nitrogen is a straight or branched alkyl group 
of four carbons or feWer. 
In another embodiment, a composition is provided com 
prising a pharmaceutically acceptable carrier and a com 
pound as described above. 
In another embodiment, a method is provided for selec 
tively modulating the function of a nicotinic acetylcholine 
receptor comprising administering a therapeutically effective 
amount of a compound as described above to a mammalian 
subject in need thereof. 
In another embodiment, a method is provided for facilitat 
ing transport of a compound of the invention into the central 
nervous system by interaction of the compound With the 
blood brain barrier choline transporter. 
In another embodiment, a method is provided for prevent 
ing and/ or treating a central nervous system associated disor 
der, for example, schizophrenia, Tourettes’, Huntington’s 
Chorea, Parkinson’s disease, AlZheimer’s disease, and 
related conditions, comprising administering a therapeuti 
cally effective amount of a compound as described above to a 
mammalian subject in need thereof. 
In another embodiment, a method is provided for prevent 
ing and/or treating substance use and/or abuse comprising 
administering a therapeutically effective amount of a com 
pound as described above to a mammalian subject in need 
thereof. 
In another embodiment, a method is provided for prevent 
ing and/ or treating gastrointestinal tract disorders comprising 
administering a therapeutically effective amount of a com 
pound as described above to a mammalian subject in need 
thereof. 
Other methods, features and advantages of the present 
invention Will be or become apparent to one With skill in the 
art upon examination of the folloWing detailed descriptions. It 
is intended that all such additional methods, features and 
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advantages be included Within this description, be Within the 
scope of the present invention, and be protected by the accom 
panying claims. 
DETAILED DESCRIPTION OF THE INVENTION 
Before the present compositions and methods are 
described, it is to be understood that the invention is not 
limited to the particular methodologies, protocols, assays, 
and reagents described, as these may vary. It is also to be 
understood that the terminology used herein is intended to 
describe particular embodiments of the present invention, and 
is in no Way intended to limit the scope of the present inven 
tion as set forth in the appended claims. 
It must be noted that as used herein and in the appended 
claims, the singular forms “a,” “an,” and “the” include plural 
references unless the context clearly dictates otherWise. 
Unless de?ned otherWise, all technical and scienti?c terms 
used herein have the same meanings as commonly under 
stood by one of ordinary skill in the art to Which this invention 
belongs. All publications cited herein are incorporated herein 
by reference in their entirety for the purpose of describing and 
disclosing the methodologies, reagents, and tools reported in 
the publications that might be used in connection With the 
invention. Nothing herein is to be construed as an admission 
that the invention is not entitled to antedate such disclosure by 
virtue of prior invention. 
The term “nicotinic acetylcholine receptor” refers to the 
endogenous acetylcholine receptor having binding sites for 
acetylcholine Which also bind to nicotine. The term “nicotinic 
acetylcholine receptor” includes the term “neuronal nicotinic 
acetylcholine receptor.” 
The terms “subtype of nicotinic acetylcholine receptor,” 
and “nicotinic acetylcholine receptor subtype” refer to vari 
ous subunit combinations of the nicotinic acetylcholine 
receptor, and may refer to a particular homomeric or hetero 
meric complex, or multiple homomeric or heteromeric com 
plexes. 
The term “choline transporter” refers to the endogenous 
choline transporter having binding sites for choline Which 
also bind to positively charged quaternary ammonium 
groups. The term “choline transporter” includes the term 
“blood brain barrier choline transporter.” 
The term “agonist” refers to a substance Which interacts 
With a receptor and increases or prolongs a physiological 
response (i.e. activates the receptor). 
The term “partial agonist” refers to a substance Which 
interacts With and activates a receptor to a lesser degree than 
an agonist. 
The term “antagonist” refers to a substance Which interacts 
With and decreases the extent or duration of a physiological 
response of that receptor. 
The terms “disorder,” “disease,” and “condition” are used 
inclusively and refer to any status deviating from normal. 
The term “central nervous system associated disorders” 
includes any cognitive, neurological, and mental disorders 
causing aberrant or pathological neural signal transmission, 
such as disorders associated With the alteration of normal 
neurotransmitter release in the brain. 
The term “loWer alkyl” refers to straight or branched chain 
alkyl radicals having in the range of l to 4 carbon atoms. 
The term “alkyl” refers to straight or branched chain alkyl 
radicals having 1 to 19 carbon atoms, and “substituted alkyl” 
refers to alkyl radicals further bearing one or more substitu 
ents including, but not limited to, hydroxy, alkoxy (of a loWer 
alkyl group), mercapto (of a loWer alkyl group), aryl, hetero 
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cyclic, halogen, tri?uoromethyl, cyano, nitro, amino, car 
boxyl, carbamate, sulfonyl, and sulfonamide. 
The term “cycloalkyl” refers to cyclic ring-containing moi 
eties containing 3 to 8 carbon atoms, and “substituted 
cycloalkyl” refers to cycloalkyl moieties further bearing one 
or more substituents as set forth above. 
The term “alkenyl” refers to straight or branched chain 
hydrocarbyl groups having at least one carbon-carbon double 
bond and having 2 to 19 carbon atoms, and “substituted 
alkenyl” refers to alkenyl groups further bearing one or more 
substituents as set forth above. 
The term “alkynyl” refers to straight or branched chain 
hydrocarbyl moieties having at least one carbon-carbon triple 
bond and having 2 to 19 carbon atoms, and “substituted 
alkynyl” refers to alkynyl moieties further bearing one or 
more substituents as set forth above. 
The term “aryl” refers to aromatic groups having 6 to 24 
carbon atoms, and “substituted aryl” refers to aryl groups 
further bearing one or more substituents as set forth above. 
The term “alkylaryl” refers to alkyl-substituted aryl 
groups, and “substituted alkylaryl” refers to alkylaryl groups 
further bearing one or more substituents as set forth above. 
The term “arylalkyl” refers to aryl-substituted alkyl 
groups, and “substituted arylalkyl” refers to arylalkyl groups 
further bearing one or more substituents as set forth above. 
The term “arylalkenyl” refers to aryl-substituted alkenyl 
groups, and “substituted arylalkenyl” refers to arylalkenyl 
groups further bearing one or more substituents as set forth 
above. 
The term “arylalkynyl” refers to aryl-substituted alkynyl 
groups, and “substituted arylalkynyl” refers to arylalkynyl 
groups further bearing one or more substituents as set forth 
above. 
The term “heterocyclic” refers to cyclic moieties contain 
ing one or more heteroatoms as part of the ring structure and 
having 3 to 24 carbon atoms, and “substituted heterocyclic” 
refers to heterocyclic moieties further bearing one or more 
substituents as set forth above. 
The term “acyl” refers to alkyl-carbonyl groups, and “sub 
stituted acyl” refers to acyl groups further bearing one or 
more substituents as set forth above. 
The term “halogen” refers to ?uoride, chloride, bromide or 
iodide groups. 
It is understood that in all substituted groups de?ned above, 
polymers arrived at by de?ning sub stituents With further sub 
stituents to themselves (e. g. substituted aryl having a substi 
tuted aryl group as a substituent Which is itself substituted 
With a substituted aryl group, etc.) are not intended for inclu 
sion herein. In such cases, the maximum number of such 
substituents is three. That is to say that each of the above 
de?nitions is constrained by a limitation that, for example, 
substituted aryl groups are limited to -substituted aryl-(sub 
stituted aryl)-sub stituted aryl. 
Compounds of the present invention are bis-quaternary 
ammonium cyclophane compounds corresponding to For 
mula (I): 
X16 and X26 are each independently an organic or inor 
ganic anion. 
US 8,653,275 B2 
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Q and T are each independently attached to R1 and R2. Q 
and T are each independently selected from alkyl, substituted 
alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, substituted 
alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, 
alkylaryl, substituted alkylaryl, arylalkyl, substituted aryla 
lkyl, arylalkenyl, substituted arylalkenyl, arylalkynyl, substi 
tuted arylalkynyl, heterocyclic, substituted heterocyclic; 
SOYl, SO2Y1, SO2OYl or SO2NHYl, where Y1 is selected 
from hydrogen, lower alkyl, alkenyl, alkynyl or aryl, and 
where Y1 is not hydrogen in SOYl and if Y1 is alkenyl or 
alkynyl, the site of unsaturation is not conjugated With a 
heteroatom; COY2, Where Y2 is selected from hydrogen, 
alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, 
alkoxy, alkenyl, substituted alkenyl, alkynyl, substituted 
alkynyl, aryl, substituted aryl, aryloxy, alkylaryl, substituted 
alkylaryl, arylalkyl, substituted arylalkyl, arylalkenyl, substi 
tuted arylalkenyl, arylalkynyl, substituted arylalkynyl, het 
erocyclic, or substituted heterocyclic, and Where if Y2 com 
prises alkenyl or alkynyl, the site of unsaturation is not 
conjugated With the carbonyl group; 0Y3, Where Y3 is 
selected from hydrogen, alkyl, substituted alkyl, cycloalkyl, 
substituted cycloalkyl, alkenyl, substituted alkenyl, alkynyl, 
substituted alkynyl, aryl, substituted aryl, alkylaryl, substi 
tuted alkylaryl, arylalkyl, substituted arylalkyl, arylalkenyl, 
substituted arylalkenyl, arylalkynyl, substituted arylalkynyl, 
acyl, alkylsulfonyl, arylsulfonyl, heterocyclic, or substituted 
heterocyclic, Where if Y3 comprises alkenyl or alkynyl, the 
site of unsaturation is not conjugated With the oxygen; 
NY4Y5, Where Y4 and Y5 are each independently selected 
from hydrogen, alkyl, substituted alkyl, cycloalkyl, substi 
tuted cycloalkyl, alkenyl, substituted alkenyl, alkynyl, substi 
tuted alkynyl, aryl, substituted aryl, alkylaryl, substituted 
alkylaryl, arylalkyl, substituted arylalkyl, arylalkenyl, substi 
tuted arylalkenyl, arylalkynyl, substituted arylalkynyl, acyl, 
alkylsulfonyl, arylsulfonyl, heterocyclic, or substituted het 
erocyclic, Where if Y4 orY5 comprises alkenyl or alkynyl, the 
site of unsaturation is not conjugated With the nitrogen; SY6, 
Where Y6 is selected from hydrogen, alkyl, substituted alkyl, 
cycloalkyl, substituted cycloalkyl, alkenyl, substituted alk 
enyl, alkynyl, substituted alkynyl, aryl, substituted aryl, alky 
laryl, substituted alkylaryl, arylalkyl, substituted arylalkyl, 
arylalkenyl, substituted arylalkenyl, arylalkynyl, substituted 
arylalkynyl, heterocyclic, or substituted heterocyclic, and 
Where if Y6 comprises alkenyl or alkynyl, the site of unsat 
uration is not conjugated With the sulfur. 
R1 and R2 are each independently ?ve or six membered 
rings as shoWn in formulas (HA) and (HB), Wherein each ring 
of R1 and R2 has one, tWo or three nitrogen atoms, each ring 
of R1 and R2 has one quaterniZed nitrogen, and tWo of R3 
through R24 of each R1 and tWo of R3 through R24 of each R2 
are replaced by one attachment to Q and one attachment to T. 
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8 
-continued 
(HB) 
R24 
Al is carbon or nitrogen, provided that WhenAl joins a ring 
atom With an unsaturated bond or is a nitrogen, R3 is absent, 
and When A1 joins a ring atom With an unsaturated bond and 
is a nitrogen, both R3 and R4 are absent. 
A2 is carbon or nitrogen, provided that When A2 joins a ring 
atom With an unsaturated bond or is a nitrogen, R5 is absent, 
and When A2 joins a ring atom With an unsaturated bond and 
is a nitrogen, both R5 and R6 are absent. 
A3 is carbon or nitrogen, provided that When A3 joins a ring 
atom With an unsaturated bond or is a nitrogen, R7 is absent, 
and When A3 joins a ring atom With an unsaturated bond and 
is a nitrogen, both R7 and R8 are absent. 
A4 is carbon or nitrogen, provided that When A4 joins a ring 
atom With an unsaturated bond or is a nitrogen, R9 is absent, 
and When A4 joins a ring atom With an unsaturated bond and 
is a nitrogen, both R9 and R10 are absent. 
A5 is carbon or nitrogen, provided that When A5 joins a ring 
atom With an unsaturated bond or is a nitrogen, R1 1 is absent, 
and When A5 joins a ring atom With an unsaturated bond and 
is a nitrogen, both R11 and R12 are absent. 
A6 is carbon or nitrogen, provided that When A6 joins a ring 
atom With an unsaturated bond or is a nitrogen, R13 is absent, 
and When A6 joins a ring atom With an unsaturated bond and 
is a nitrogen, both R13 and R14 are absent. 
A7 is carbon or nitrogen, provided that When A7 joins a ring 
atom With an unsaturated bond or is a nitrogen, R15 is absent, 
and When A7 joins a ring atom With an unsaturated bond and 
is a nitrogen, both R15 and R16 are absent. 
A8 is carbon or nitrogen, provided that When A8 joins a ring 
atom With an unsaturated bond or is a nitrogen, R17 is absent, 
and When A8 joins a ring atom With an unsaturated bond and 
is a nitrogen, both R17 and R18 are absent. 
A9 is carbon or nitrogen, provided that When A9 joins a ring 
atom With an unsaturated bond or is a nitrogen, R19 is absent, 
and When A9 joins a ring atom With an unsaturated bond and 
is a nitrogen, both R19 and R20 are absent. 
A10 is carbon or nitrogen, provided that When A10 joins a 
ring atom With an unsaturated bond or is a nitrogen, R21 is 
absent, and When A10 joins a ring atom With an unsaturated 
bond and is a nitrogen, both R21 and R22 are absent. 
All is carbon or nitrogen, provided that When All joins a 
ring atom With an unsaturated bond or is a nitrogen, R23 is 
absent, and When All joins a ring atom With an unsaturated 
bond and is a nitrogen, both R23 and R24 are absent. 
R3’ R4’ R5’ R6’ R7’ R8’ R9’ R10’ R11’ R12’ R13 and R14’ or 
R15’ R16’ R17’ R18’ R19’ R20’ R21’ R22’ R23 and R24’ When 
present, are each independently selected from hydrogen, 
alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, 
alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, 
aryl, substituted aryl, alkylaryl, substituted alkylaryl, aryla 
lkyl, substituted arylalkyl, arylalkenyl, substituted arylalk 
enyl, arylalkynyl, substituted arylalkynyl, heterocyclic, sub 
stituted heterocyclic, halo, cyano, nitro; or tWo adjacent 
groups R3 through R14, or groups R15 through R24, together 
With the atoms to Which they are attached on the ring of (HA) 
or (HB) independently form a three to eight member cyclol 
kane, substituted cycloalkane, cycloalkene, substituted 
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cycloalkene, aryl, substituted aryl, heterocycle With one to 
three hetero atoms of nitrogen, oxygen or sulfur in the ring, or 
substituted heterocycle With one to three hetero atoms of 
nitrogen, oxygen or sulfur in the ring; and When all of the 
bonds to the ring ammonium nitrogen are saturated, then any 
OfR3’ R4’ R5’ R6’ R7’ R8’ R9’ R10’ R11’ R12’ R13’ R14’ R15’ R16, 
R17, R18, R19, R20, R21, R22, R23 or R24 Which is attached to 
the ammonium nitrogen is a straight or branched alkyl group 
of four carbons or feWer. 
For example, R1 and R2 include pyrrole, pyrrolidine, pyra 
Zole, imidaZole, 1,2,3-triazole, l,2,4-triaZole, pyridine, pyri 
midine, piperidine, quinoline, tetrahydroquinoline, isoquino 
line, tetrahydroisoquinoline, pyraZine, piperaZine, pyridaZine 
and triaZine. 
As another example, R3, R4, R5, R6, R7, R8, R9, R10, R11, 
R12’ R13’ R14’ R15’ R16’ R17’ R18’ R19’ R20’ R21’ R22’ R23 and 
R24, include hydrogen, methyl, ethyl, propyl, butyl, 
hydroxymethyl, hydroxyethyl, hydroxypropyl, tri?uorom 
ethyl, chloro, bromo, phenyl, pyrrolidine, N-alkyl pyrrolidine 
(for example Where the alkyl chain is methyl, ethyl or propyl), 
unsaturated pyrrolidine, unsaturated N-alkyl pyrrolidine (for 
example Where the alkyl chain is methyl, ethyl or propyl), 
aZiridine, N-methyl aZiridine, aZetidine, N-methyl aZetidine, 
unsaturated aZetidine, unsaturated N-methyl aZetidine, pip 
eridine, N-methyl piperidine, unsaturated piperidine, unsat 
urated N-methyl piperidine, aZepane, N-methyl aZepane, 
unsaturated aZepane, unsaturated N-methyl aZepane, aZo 
cane, N-methyl aZocane, unsaturated aZocane, unsaturated 
N-methyl aZocane, l-aZa-bicyclo[3.2.l]octane, l-aZa-bicy 
clo[2.2.l]heptane, 8-methyl-8-aZa-bicyclo[3.2.l]octane, 
l-aZa-tricyclo[3.3.l.l3’7]decane, methyl cycloalkyl, methyl 
substituted cycloalkyl, methylpyrrolidine, methyl N-alkyl 
pyrrolidine (for example Where the alkyl chain is methyl, 
ethyl or propyl), methyl unsaturated pyrrolidine, methyl 
unsaturated N-alkyl pyrrolidine (for example Where the alkyl 
chain is methyl, ethyl or propyl), methyl aZiridine, methyl 
N-methyl aZiridine, methyl aZetidine, methyl N-methyl aZe 
tidine, methyl unsaturated aZetidine, methyl unsaturated 
N-methyl aZetidine, methyl piperidine, methyl N-methyl pip 
eridine, methyl unsaturated piperidine, methyl unsaturated 
N-methyl piperidine, methyl aZepane, methyl N-methyl 
aZepane, methyl unsaturated aZepane, methyl unsaturated 
N-methyl aZepane, methyl aZocane, methyl N-methyl aZo 
cane, methyl unsaturated aZocane, methyl unsaturated N-me 
thyl aZocane, methyl-l-aZa-bicyclo[3.2.l]octane, methyl-l 
aZa-bicyclo[2.2.l]heptane, 8-methyl-8-aZa-bicyclo[3.2.l] 
octane, and methyl-l -aZa-tricyclo[3.3 .l .l3’7]decane. 
As a further example, When tWo adjacent groups R3 
through R14, or groups R15 through R24, together With the 
atoms to Which they are attached on the ring of (IIA) or (IIB) 
independently form a three to eight member cyclolkane, sub 
stituted cycloalkane, cycloalkene, substituted cycloalkene, 
aryl, substituted aryl, heterocycle With one to three hetero 
atoms of nitrogen, oxygen or sulfur in the ring, or substituted 
heterocycle With one to three hetero atoms of nitrogen, oxy 
gen or sulfur in the ring. For example, possible rings include 
benZene, pyridine, pyran, indene, isoindene, benZofuran, 
isobenZofuran, benZo[b]thiophene, benZo[c]thiophene, 
indole, indolenine, isoindole, cyclopental[b]pyridine, pyrano 
[3,4-b]pynrole, indaZole, indoxaZine, benZoxaZole, anthranil, 
naphthalene, tetralin, decalin, chromene, coumarin, chro 
man-4-one, isocoumarin, isochromen-3-one, quinoline, iso 
quinoline, cinnoline, quinaZoline, naphthyrdine, pyrido[3,4 
b]-pyridine, pyridol[3,2-b]pyridine, pyrido[4,3,-b]-pyridine, 
benZoxaZine, anthracene, phenanthrene, phenalene, ?uorene, 
caraZole, xanthene, acnidine, octahydro-[l]pyridine, l-me 
thyloctahydro-[l]pyridine, octahydroindole, l-methyloc 
20 
25 
30 
35 
40 
45 
50 
55 
60 
65 
10 
tahydro-indole, octahydro-cyclopenta[b]pyrrole, l-methy 
loctahydro-cyclopenta[b]pyrrole, decahydroquinoline, and 
l -methyldecahydroquinoline. 
X16 and X26, for example, include F', Cl“, Br“, I“, N02“, 
HSO4_, S04‘, HPO4_, PO42‘, methanesulfonate, tri?uo 
romethane sulfate, p-toluenesulfonate, benZenesulfonate, 
salicylate, proprionate, ascorbate, aspar‘tate, fumarate, galac 
tarate, maleate, citrate, glutamate, glycolate, lactate, malate, 
maleate, tartrate, oxalate, succinate, or similar pharmaceuti 
cally acceptable organic acid addition salts, including the 
pharmaceutically acceptable salts listed in the Journal of 
Pharmaceutical Sciences volume 66, page 2, 1977, Which are 
hereby incorporated by reference. The above salt forms may 
be in some cases hydrates or solvates With alcohols and other 
solvents. 
In a compound of Formula (I), preferably R1 and R2 are 
six-membered, aromatic rings. More preferably, R1 and R2 
are pyridinium rings, such as 1,3-substituted pyridinium 
rings. 
In a compound of Formula (I), preferably R3, R4, R5, R6, 
R7’ R8’ R9’ R10’ R11’ R12’ R13’ R14’ R15’ R16’ R17’ R18’ R19’ 
R20, R21, R22, R23 or R24 is absent or is hydrogen. 
In a compound of Formula (I), preferably Q is attached to 
the nitrogen of a pyridinium ring of R1 and R2. In other 
preferred embodiments, Q is attached to the nitrogen of a 
pyridinium ring of R1 and a carbon at the 3-position of a 
pyridinium ring of R2. Preferably, Q is an alkyl group; more 
In a compound of Formula (I), preferably T is attached to 
the carbon at the 3-position of a pyridinium ring of R1 and R2. 
In other preferred embodiments, T is attached to the nitrogen 
of a pyridinium ring of R2 and a carbon at the 3-position of a 
pyridinium ring of R1. Preferably, T is an alkyl group or a 
4CEC-alkyl-CEC-group; more preferably, T is selected 
from i(CH2) 12* or iCECi(CH2)6iCECi. 
In a compound of Formula (I), preferably X16 and X26 are 
halogens. More preferably, X16 and X26 are bromide or 
iodide. 
In another embodiment, the compound of Formula (I) is 
de?ned wherein R1 and R2 are 1,3-substituted pyridinium 
rings: Q is *(CH2)4*> i(CH2)6i$ i(CH2)8is 
*(CH2)9*> *(CH2)10*: *(CH2)11* or *(CH2)12*: T 
is i(CH2) 12* or 4CECi(CH2)6iCECi, and X1 and 
X2 are bromide or iodide. 
Exemplary compounds of the present invention include: 
N,N'-(l ,6-hexanediyl)-3,3'-(l ,9-decanediyn-l , l 0-diyl)-bis 
pyridinium diiodide; 
N,N'-(l ,8-octananediyl) -3 ,3'-( l , 9-decanediyn- l , l 0-diyl) 
bis-pyridinium diiodide; 
N,N'-(l ,9-nonanediyl)-3,3'-(l ,9-decanediyn- l , l 0-diyl)-bis 
pyridinium dibromide; 
N,N'-(l , l 0-decanediyl)-3,3'-(l ,9-decanediyn-l , l0-diyl)-bis 
pyridinium diiodide; 
N,N'-(l ,l l-undecanediyl) -3 ,3'-( l , 9-decanediyn- l , l 0-diyl) 
bis-pyridinium dibromide; 
N,N'-(l ,4-butanediyl) -3 ,3'-(l , l 2-dodecanediyl) -bis-pyri 
dinium diiodide; 
N,3'-(l,l2-dodecanediyl)-3,N'-(l,l2-dodecanediyl)-bis-py 
ridinium dibromide. 
The compounds of the present invention may contain one 
or more stereocenters. The invention includes all possible 
diastereomers and all enantiomeric forms as Well as all com 
binations of diasteriomers and enantiomers, including race 
mic mixtures. The compounds can be separated into substan 
tially optically pure compounds. 
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Compounds of the present invention can be prepared, for 
example, from corresponding bases by reaction With an 
appropriate alkyl bromide. 
The compounds of the invention are nicotinic acetylcho 
line receptor agents. Thus, they may augment or inhibit [3 H] 
nicotine binding, [3H]MLA binding, evoke or inhibit neu 
rotransmitter release, and/or evoke or inhibit the ?ux of ions 
through the nicotinic receptor. Moreover, the compounds of 
the invention may act either at presynaptic sites or postsyn 
aptic sites, for example, at a postsynaptic acetylcholine recep 
tor containing an (X7 subunit. When acting at a postsynaptic 
site, neurotransmitter release per se is not altered. Rather, the 
compounds of the invention may act by interacting With a 
postsynaptic acetylcholine receptor to change the membrane 
potential of the cell, thereby increasing or decreasing the 
likelihood of ?ring an action potential. Alternatively, interac 
tion of a compound of the invention With a postsynaptic 
acetylcholine receptor may result in the alteration of one or 
more second messenger systems Within the cell so as to 
decrease or increase the nicotinic cholinergic response. 
In one embodiment, the present invention relates to a 
method for selectively modulating the function of a nicotinic 
acetylcholine receptor comprising administering to a mam 
malian subject in need thereof a therapeutically effective 
amount of a compound of Formula (I). In such a method, the 
compound of Formula (I) may selectively bind to one or more 
subtypes of nicotinic acetylcholine receptor. The compound 
of Formula (I) may act as an agoinst or partial agonist of 
nicotinic acetylcholine receptor function. Hence the com 
pound of Formula (I) may increase or prolong the release of a 
neurotransmitter from a central nervous system tissue. The 
neurotransmitter affected may include dopamine, norepi 
nephrine, serotonin, gamma-aminobutryic acid, or glutamate. 
Alternatively, the compound of Formula (I) may act as an 
antagonist of nicotinic acetylcholine receptor function. 
Hence the compound of Formula (I) may decrease the extent 
or duration of the release of a neurotransmitter from a central 
nervous system tissue. In this regard, the compound of For 
mula (I) may act by decreasing stimulant-evoked neurotrans 
mitter release. The neurotransmitter affected may include 
dopamine, norepinephrine, serotonin, gamma-aminobutryic 
acid, or glutamate. Alternatively, the compound of Formula 
(I) may act by interacting With a postsynaptic acetylcholine 
receptor to change the membrane potential of the cell thereby 
increasing or decreasing the likelihood of ?ring an action 
potential, or to alter one or more second messenger systems 
Within the cell so as to decrease or increase the nicotinic 
cholinergic response. 
In another embodiment, the present invention is directed to 
a method of facilitating transport of a compound of Formula 
(I) into the central nervous system by interaction of the com 
pound With the blood brain barrier choline transporter. Com 
pounds of Formula (I) have high af?nity for blood brain 
barrier choline transporters and have the potential to be 
actively transported into the CNS by this transporter. Choline 
transport at the blood brain barrier is a sodium-independent, 
carrier-mediated, and saturable process. The choline trans 
porter binding site contains an anionic binding area that binds 
positively charged quaternary ammonium groups. Recent 
reports have shoWn that this transporter is ef?cacious in deliv 
ering quaternary ammonium analogs to the CNS. The quater 
nary ammonium structural characteristic of the compounds of 
Formula (I) provides a unique synergistic combination of 
nicotinic receptor interaction and af?nity for the blood brain 
barrier choline transporter to maximiZe transport into the 
central nervous system. 
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In another embodiment, the present invention is directed to 
a method for preventing and/or treating a central nervous 
system associated disorder comprising administering to a 
mammalian subject in need thereof a therapeutically effective 
amount of a compound of Formula (I). In such a method, the 
compound of Formula (I) may selectively bind to one or more 
subtypes of nicotinic acetylcholine receptor. The compound 
of Formula (I) may act as an agoinst or partial agonist of 
nicotinic acetylcholine receptor function. Hence the com 
pound of Formula (I) may increase or prolong the release of a 
neurotransmitter from a central nervous system tissue. The 
neurotransmitter affected may include dopamine, norepi 
nephrine, serotonin, gamma-aminobutryic acid, or glutamate. 
Alternatively, the compound of Formula (I) may act as an 
antagonist of nicotinic acetylcholine receptor function. 
Hence the compound of Formula (I) may decrease the extent 
or duration of the release of a neurotransmitter from a central 
nervous system tissue. In this regard, the compound of For 
mula (I) may act by decreasing stimulant-evoked neurotrans 
mitter release. The neurotransmitter affected may include 
dopamine, norepinephrine, serotonin, gamma-aminobutryic 
acid, or glutamate. Alternatively, the compound of Formula 
(I) may act by interacting With a postsynaptic acetylcholine 
receptor to change the membrane potential of the cell thereby 
increasing or decreasing the likelihood of ?ring an action 
potential, or to alter one or more second messenger systems 
Within the cell so as to decrease or increase the nicotinic 
cholinergic response. 
Central nervous system disorders Which may be treated 
according to the method of the present invention include 
AlZheimer’s disease, dementia, cognitive dysfunctions (in 
cluding disorders of attention, focus and concentration), 
attention de?cit disorders, affective disorders, extrapyrami 
dal motor function disorders, Parkinson’s disease, progres 
sive supramolecular palsy, Huntington’s disease, Gilles de la 
Tourette syndrome, tardive dyskinesia, neuroendocrine dis 
orders, dysregulation of food intake, disorders of nociception, 
pain, mood and emotional disorders, depression, panic anxi 
ety, psychosis, schizophrenia, or epilepsy. 
In yet another embodiment, the present invention is 
directed to a method for preventing and/ or treating sub stance 
use and/or abuse comprising administering to a mammalian 
subject in need thereof a therapeutically effective amount of a 
compound of Formula (I). In such a method, the compound of 
Formula (I) may selectively bind to one or more subtypes of 
nicotinic acetylcholine receptor. The compound of Formula 
(I) may act as an agonist or partial agonist of nicotinic ace 
tylcholine receptor function. Hence the compound of For 
mula (I) may increase or prolong the release of a neurotrans 
mitter from a central nervous system tissue. The 
neurotransmitter affected may include dopamine, norepi 
nephrine, serotonin, gamma-aminobutryic acid, or glutamate. 
Alternatively, the compound of Formula (I) may act as an 
antagonist of nicotinic acetylcholine receptor function. 
Hence the compound of Formula (I) may decrease the extent 
or duration of the release of a neurotransmitter from a central 
nervous system tissue. In this regard, the compound of For 
mula (I) may act by decreasing stimulant-evoked neurotrans 
mitter release. The neurotransmitter affected may include 
dopamine, norepinephrine, serotonin, gamma-aminobutryic 
acid, or glutamate. Alternatively, the compound of Formula 
(I) may act by interacting With a postsynaptic acetylcholine 
receptor to change the membrane potential of the cell thereby 
increasing or decreasing the likelihood of ?ring an action 
potential, or to alter one or more second messenger systems 
Within the cell so as to decrease or increase the nicotinic 
cholinergic response. 
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The conditions of substance use and/or abuse treated 
according to the method of the present invention include 
nicotine abuse (including use in smoking cessation therapy), 
nicotine intoxication, amphetamine abuse, methamphet 
amine abuse, MDMA (methylenedioxymethamphetamine) 
abuse, methylphenidate abuse, cocaine abuse, or alcohol 
abuse. 
In another embodiment, the present invention is directed to 
a method for preventing and/or treating gastrointestinal tract 
disorders comprising administering to a mammalian subject 
in need thereof a therapeutically effective amount of a com 
pound of Formula (I). In such a method, the compound of 
Formula (I) may selectively bind to one or more subtypes of 
nicotinic acetylcholine receptor. The compound of Formula 
(I) may act as an agonist or partial agonist of nicotinic ace 
tylcholine receptor function. Hence the compound of For 
mula (I) may increase or prolong the release of a neurotrans 
mitter from a central nervous system tissue, or may increase 
or prolong the release of a neurotransmitter from a peripheral 
nervous system tissue, or may act directly on a gastrointesti 
nal tract tissue. The neurotransmitter affected may include 
dopamine, norepinephrine, serotonin, gamma-aminobutryic 
acid, or glutamate. Alternatively, the compound of Formula 
(I) may act as an antagonist of nicotinic acetylcholine recep 
tor function. Hence the compound of Formula (I) may 
decrease the extent or duration of the release of a neurotrans 
mitter from a central nervous system tissue, or may decrease 
the extent or duration of the release of a neurotransmitter from 
a peripheral nervous system tissue, or may act directly on a 
gastrointestinal tract tissue. In this regard, the compound of 
Formula (I) may act by decreasing stimulant-evoked neu 
rotransmitter release. The neurotransmitter affected may 
include dopamine, norepinephrine, serotonin, gamma-ami 
nobutryic acid, or glutamate. Alternatively, the compound of 
Formula (I) may act by interacting With a postsynaptic ace 
tylcholine receptor to change the membrane potential of the 
cell thereby increasing or decreasing the likelihood of ?ring 
an action potential, or to alter one or more second messenger 
systems Within the cell so as to decrease or increase the 
nicotinic cholinergic response. 
Gastrointestinal disorders Which may be treated according 
to the method of the present invention include irritable boWel 
syndrome, colitis, diarrhea, constipation, gastric acid secre 
tion or ulcers. 
In yet another embodiment, the present invention is 
directed to a method for preventing and/ or treating in?am 
matory tract disorders comprising administering to a mam 
malian subject in need thereof a therapeutically effective 
amount of a compound of Formula (I). In such a method, the 
compound of Formula (I) may selectively bind to one or more 
subtypes of nicotinic acetylcholine receptor. The compound 
of Formula (I) may act as an agonist or partial agonist of 
nicotinic acetylcholine receptor function. Hence the com 
pound of Formula (I) may increase or prolong the release of a 
neurotransmitter from a central nervous system tissue, or may 
increase or prolong the release of a neurotransmitter from a 
peripheral nervous system tissue, or may act directly on a 
non-nervous system tissue. The neurotransmitter affected 
may include dopamine, norepinephrine, serotonin, gamma 
aminobutryic acid, or glutamate. Alternatively, the compound 
of Formula (I) may act as an antagonist of nicotinic acetyl 
choline receptor function. Hence the compound of Formula 
(I) may decrease the extent or duration of the release of a 
neurotransmitter from a central nervous system tissue, or may 
decrease the extent or duration of the release of a neurotrans 
mitter from a peripheral nervous system tissue, or may act 
directly on a non-nervous system tissue. In this regard, the 
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compound of Formula (I) may act by decreasing stimulant 
evoked neurotransmitter release. The neurotransmitter 
affected may include dopamine, norepinephrine, serotonin, 
gamma-aminobutryic acid, or glutamate. Alternatively, the 
compound of Formula (I) may act by interacting With a 
postsynaptic acetylcholine receptor to change the membrane 
potential of the cell thereby increasing or decreasing the 
likelihood of ?ring an action potential, or to alter one or more 
second messenger systems Within the cell so as to decrease or 
increase the nicotinic cholinergic response. 
In?ammatory disorders Which may be treated according to 
the method of the present invention include adult respiratory 
distress syndrome, allergy, anemia, ankylosing spondylitis, 
asthma, atherosclerosis, bacterial infections, benign prostatic 
hyperplasia, cholecystitis, ulcerative colitis, Crohn’s disease, 
diabetes mellitus, emphysema, gastritis, glomerulonephritis, 
hypereosinophilia, irritable boWel syndrome, multiple scle 
rosis, osteoarthritis, pancreatitis, polymyositis, psoriasis and 
rheumatoid arthritis. 
The compounds of the present invention can be delivered 
directly or in pharmaceutical compositions along With suit 
able carriers or excipients, as is Well knoWn in the art. For 
example, a pharmaceutical composition of the invention may 
include a conventional additive, such as a stabiliZer, buffer, 
salt, preservative, ?ller, ?avor enancer and the like, as knoWn 
to those skilled in the art. Exemplary buffers include phos 
phates, carbonates, citrates and the like. Exemplary preserva 
tives include EDTA, EGTA, BHA, BHT and the like. 
An effective amount of such agents can readily be deter 
mined by routine experimentation, as can the most effective 
and convenient route of administration and the most appro 
priate formulation. Various formulations and drug delivery 
systems are available in the art. See, e.g., Gennaro, A. R., ed. 
(1995) Remington’s Pharmaceutical Sciences. 
Suitable routes of administration may, for example, 
include oral, rectal, transmucosal, transdermal, topical, nasal, 
or intestinal administration and parenteral delivery, including 
intramuscular, subcutaneous, intramedullary injections, as 
Well as intrathecal, direct intraventricular, intravenous, intra 
peritoneal, intranasal, or intraocular injections. In addition, 
the agent or composition thereof may be administered sub 
lingually or via a spray, including a sublingual tablet or a 
sublingual spray. The agent or composition thereof may be 
administered in a local rather than a systemic manner. For 
example, a suitable agent can be delivered via injection or in 
a targeted drug delivery system, such as a depot or sustained 
release formulation. 
The pharmaceutical compositions of the present invention 
may be manufactured by any of the methods Well-knoWn in 
the art, such as by conventional mixing, dissolving, granulat 
ing, dragee-making, levigating, emulsifying, encapsulating, 
entrapping, or lyophiliZing processes. As noted above, the 
compositions of the present invention can include one or 
more physiologically acceptable carriers such as excipients 
and auxiliaries that facilitate processing of active molecules 
into preparations for pharmaceutical use. 
Proper formulation is dependent upon the route of admin 
istration chosen. For injection, for example, the composition 
may be formulated in aqueous solutions, preferably in physi 
ologically compatible buffers such as Hanks’ solution, Ring 
er’ s solution, or physiological saline buffer. For transmucosal 
or nasal administration, penetrants appropriate to the barrier 
to be permeated are used in the formulation. Such penetrants 
are generally knoWn in the art. In a preferred embodiment of 
the present invention, the present compounds are prepared in 
a formulation intended for oral administration. For oral 
administration, the compounds can be formulated readily by 
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combining the active compounds With pharmaceutically 
acceptable carriers Well known in the art. Such carriers enable 
the compounds of the invention to be formulated as tablets, 
pills, dragees, capsules, liquids, gels, syrups, slurries, suspen 
sions and the like, for oral ingestion by a subject. The com 
pounds may also be formulated in rectal compositions such as 
suppositories or retention enemas, e.g., containing conven 
tional suppository bases such as cocoa butter or other glyc 
erides. 
Pharmaceutical preparations for oral use canbe obtained as 
solid excipients, optionally grinding a resulting mixture, and 
processing the mixture of granules, after adding suitable aux 
iliaries, if desired, to obtain tablets or dragee cores. Suitable 
excipients are, in particular, ?llers such as sugars, including 
lactose, sucrose, mannitol, or sorbitol; cellulose preparations 
such as, for example, maize starch, Wheat starch, rice starch, 
potato starch, gelatin, gum tragacanth, methyl cellulose, 
hydroxypropylmethyl-cellulose, sodium carboxymethylcel 
lulose, and/or polyvinylpyrrolidone (PVP). If desired, disin 
tegrating agents may be added, such as the cross-linked poly 
vinyl pyrrolidone, agar, or alginic acid or a salt thereof such as 
sodium alginate. Also, Wetting agents such as sodium dodecyl 
sulfate may be included. 
Dragee cores are provided With suitable coatings. For this 
purpose, concentrated sugar solutions may be used, Which 
may optionally contain gum arabic, talc, polyvinyl pyrroli 
done, carbopol gel, polyethylene glycol, and/or titanium 
dioxide, lacquer solutions, and suitable organic solvents or 
solvent mixtures. Dyestuffs or pigments may be added to the 
tablets or dragee coatings for identi?cation or to characterize 
different combinations of active compound doses. 
Pharmaceutical preparations for oral administration 
include push-?t capsules made of gelatin, as Well as soft, 
sealed capsules made of gelatin and a plasticizer, such as 
glycerol or sorbitol. The push-?t capsules can contain the 
active ingredients in admixture With ?ller such as lactose, 
binders such as starches, and/or lubricants such as talc or 
magnesium stearate and, optionally, stabilizers. In soft cap 
sules, the active compounds may be dissolved or suspended in 
suitable liquids, such as fatty oils, liquid paraf?n, or liquid 
polyethylene glycols. In addition, stabilizers may be added. 
All formulations for oral administration should be in dosages 
suitable for such administration. 
In one embodiment, the compounds of the present inven 
tion can be administered transderrnally, such as through a skin 
patch, or topically. In one aspect, the transderrnal or topical 
formulations of the present invention can additionally com 
prise one or multiple penetration enhancers or other effectors, 
including agents that enhance migration of the delivered com 
pound. Transderrnal or topical administration could be pre 
ferred, for example, in situations in Which location speci?c 
delivery is desired. 
For administration by inhalation, the compounds for use 
according to the present invention are conveniently delivered 
in the form of an aerosol spray presentation from pressurized 
packs or a nebulizer, With the use of a suitable propellant, e.g., 
dichlorodi?uoromethane, trichloro?uoromethane, dichlo 
rotetra?uoroethane, carbon dioxide, or any other suitable gas. 
In the case of a pressurized aerosol, the appropriate dosage 
unit may be determined by providing a valve to deliver a 
metered amount. Capsules and cartridges of, for example, 
gelatin, for use in an inhaler or insuf?ator may be formulated. 
These typically contain a poWder mix of the compound and a 
suitable poWder base such as lactose or starch. 
Compositions formulated for parenteral administration by 
injection, e. g., by bolus injection or continuous infusion can 
be presented in unit dosage form, e.g., in ampoules or in 
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multi-dose containers, With an added preservative. The com 
positions may take such forms as suspensions, solutions, or 
emulsions in oily or aqueous vehicles, and may contain for 
mulatory agents such as suspending, stabilizing and/or dis 
persing agents. Formulations for parenteral administration 
include aqueous solutions or other compositions in Water 
soluble form. 
Suspensions of the active compounds may also be prepared 
as appropriate oily injection suspensions. Suitable lipophilic 
solvents or vehicles include fatty oils such as sesame oil and 
synthetic fatty acid esters, such as ethyl oleate or triglycer 
ides, or liposomes. Aqueous injection suspensions may con 
tain substances that increase the viscosity of the suspension, 
such as sodium carboxymethyl cellulose, sorbitol, or dextran. 
Optionally, the suspension may also contain suitable stabiliz 
ers or agents that increase the solubility of the compounds to 
alloW for the preparation of highly concentrated solutions. 
Alternatively, the active ingredient may be in poWder form for 
constitution With a suitable vehicle, e.g., sterile pyrogen-free 
Water, before use. 
As mentioned above, the compositions of the present 
invention may also be formulated as a depot preparation. 
Such long acting formulations may be administered by 
implantation (for example, subcutaneously or intramuscu 
larly) or by intramuscular injection. Thus, for example, the 
present compounds may be formulated With suitable poly 
meric or hydrophobic materials (for example as an emulsion 
in an acceptable oil) or ion exchange resins, or as sparingly 
soluble derivatives, for example, as a sparingly soluble salt. 
Suitable carriers for the hydrophobic molecules of the 
invention are Well knoWn in the art and include co-solvent 
systems comprising, for example, benzyl alcohol, a nonpolar 
surfactant, a Water-miscible organic polymer, and an aqueous 
phase. The co-solvent system may be the VPD co-solvent 
system. VPD is a solution of 3% W/v benzyl alcohol, 8% W/v 
of the nonpolar surfactant polysorbate 80, and 65% W/v poly 
ethylene glycol 300, made up to volume in absolute ethanol. 
The VPD co-solvent system (VPD15W) consists of VPD 
diluted 1:1 With a 5% dextrose in Water solution. This co 
solvent system is effective in dissolving hydrophobic com 
pounds and produces loW toxicity upon systemic administra 
tion. Naturally, the proportions of a co-solvent system may be 
varied considerably Without destroying its solubility and tox 
icity characteristics. Furthermore, the identity of the co-sol 
vent components may be varied. For example, other loW 
toxicity nonpolar surfactants may be used instead of 
polysorbate 80, the fraction size of polyethylene glycol may 
be varied, other biocompatible polymers may replace poly 
ethylene glycol, e.g., polyvinyl pyrrolidone, and other sugars 
or polysaccharides may substitute for dextrose. 
Alternatively, other delivery systems for hydrophobic mol 
ecules may be employed. Liposomes and emulsions are Well 
knoWn examples of delivery vehicles or carriers for hydro 
phobic drugs. Liposomal delivery systems are discussed 
above in the context of gene-delivery systems. Certain 
organic solvents such as dimethylsulfoxide also may be 
employed, although usually at the cost of greater toxicity. 
Additionally, the compounds may be delivered using sus 
tained-release systems, such as semi-permeable matrices of 
solid hydrophobic polymers containing the effective amount 
of the composition to be administered. Various sustained 
release materials are established and available to those of skill 
in the art. Sustained-release capsules may, depending on their 
chemical nature, release the compounds for a feW Weeks up to 
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over 100 days. Depending on the chemical nature and the 
biological stability of the therapeutic reagent, additional 
strategies for stabilization may be employed. 
For any composition used in the present methods of treat 
ment, a therapeutically effective dose can be estimated ini 
tially using a variety of techniques Well knoWn in the art. For 
example, in a cell culture assay, a dose can be formulated in 
animal models to achieve a circulating concentration range 
that includes the lC5O as determined in cell culture. Dosage 
ranges appropriate for human subjects can be determined, for 
example, using data obtained from cell culture assays and 
other animal studies. 
A therapeutically effective dose of an agent refers to that 
amount of the agent that results in amelioration of symptoms 
or a prolongation of survival in a subject. Toxicity and thera 
peutic ef?cacy of such molecules can be determined by stan 
dard pharmaceutical procedures in cell cultures or experi 
mental animals, e. g., by determining the LD5O (the dose lethal 
to 50% of the population) and the ED5O (the dose therapeuti 
cally effective in 50% of the population). The dose ratio of 
toxic to therapeutic effects is the therapeutic index, Which can 
be expressed as the ratio LDSO/EDSO. Agents that exhibit high 
therapeutic indices are preferred. 
Dosages preferably fall Within a range of circulating con 
centrations that includes the ED5O With little or no toxicity. 
Dosages may vary Within this range depending upon the 
dosage form employed and the route of administration uti 
liZed. The exact formulation, route of administration, and 
dosage should be chosen, according to methods knoWn in the 
art, in vieW of the speci?cs of a subject’s condition. 
The amount of agent or composition administered Will, of 
course, be dependent on a variety of factors, including the sex, 
age, and Weight of the subject being treated, the severity of the 
affliction, the manner of administration, and the judgment of 
the prescribing physician. 
The present compositions may, if desired, be presented in a 
pack or dispenser device containing one or more unit dosage 
forms containing the active ingredient. Such a pack or device 
may, for example, comprise metal or plastic foil, such as a 
blister pack. The pack or dispenser device may be accompa 
nied by instructions for administration. Compositions com 
prising a compound of the invention formulated in a compat 
ible pharmaceutical carrier may also be prepared, placed in an 
appropriate container, and labeled for treatment of an indi 
cated condition. 
These and other embodiments of the present invention Will 
readily occur to those of ordinary skill in the art in vieW of the 
disclosure herein, and are speci?cally contemplated. 
EXAMPLES 
The invention is further understood by reference to the 
folloWing examples, Which are intended to be purely exem 
plary of the invention. The present invention is not limited in 
scope by the exempli?ed embodiments, Which are intended as 
illustrations of single aspects of the invention only. Any meth 
ods that are functionally equivalent are Within the scope of the 
invention. Various modi?cations of the invention in addition 
to those described herein Will become apparent to those 
skilled in the art from the foregoing description. Such modi 
?cations fall Within the scope of the appended claims. 
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Example 1 
Preparation of 
Compoundl,10-bis-[(pyridin-3-yl)]-1,9-decadiyne 
\ Br 
I + 
/ 
N 
Pd(PPh3)2Cl2/CuI 
— (CH2)6 — pyrrolidine 
(CH2)s 
% % 
| \ | \ 
/ / 
N N 
1,9-Decanediyne (2.8 g, 20.9 mmol) and 3-bromopyridine 
(50 mmol) Were mixed in pyrrolidine folloWed by the addi 
tion of Pd(PPh3)2Cl2 (50 mg) and Cul (50 mg). The mixture 
Was heated to 60-700 C. for 2 h. The solvent Was removed in 
vacuum and the residue Was subjected chromatography. Hex 
ane and ethyl acetate 10:1 elute out 3-bromopyridine and 2:1 
hexane and ethyl acetate elute out the product (5.1 g, 85% 
yield) as oil. HNMR (300 MHZ, D20) 8.59 (d, 1:15 HZ, 2H), 
8.43 (dd, J:1.8 HZ, 1:51 HZ, 2H), 7.62 (dt, J:1.8 HZ, J:7.8 
HZ, 2H), 7.15 (ddd, 1:09 HZ, 1:48 HZ, J:7.8 HZ, 2H), 2.40 
(t, 1:69 HZ, 4H), 1.59-1.63 (m, 4H), 1.46-1.49 (m, 4H). 
Example 2 
Preparation of Compound N,N'-(1,6-hexanediyl)-3, 
3'-(1,9-decanediyn-1,10-diyl)-bis-pyridinium diio 
dide 
(CHM; 
3,3'-(1,9-Decanediyn-1,10-diyl)-bis-pyridine (1 mmol) 
and an equivalent of 1,6-diiodohexane Were mixed in aceto 
nitrile (1000 mL). The mixture Was re?uxed for 7 days. The 
solvent Was removed in vacuum after cooling and the result 
ing residue Was taken up in Water and partitioned betWeen 
ethyl ether and Water. The aqueous layer Was extracted exten 
sively With ethyl ether remove the starting materials. Most of 
the Water Was removed and the residue Was transferred into 
methanol. Methanol Was removed and the product Was dried 
under vacuum to afford the bis-pyridinium cyclophane (30% 
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yield). HNMR (300 MHZ, D20) 8.76 (s, 2H), 8.56 (d, 1:60 
HZ, 2H), 8.29 (d, 1:84 HZ, 2H), 7.81 (dd, 1:63 HZ, 8.1 HZ, 
2H), 4.40 (1, 1:75 HZ, 4H), 2.39 (1, 1:63 HZ, 4H), 1.85-1.84 
(m, 4H), 1.49-1.52 (m, 4H), 1.38-1.42 (m, 4H), 1.18-1.22 (m, 
4H). CNMR, 146.97, 146.26, 142.61, 128.00, 125.71, 
101.43, 73.93, 61.99, 29.94, 27.84, 27.49, 24.43, 18.90. 
Example 3 
Preparation of Compound N,N'-(1,8-octanediyl)-3, 
3'-(1,9-decanediyn-1,10-diyl)-bis-pyridinium diio 
25 
3,3'-(1,9-Decanediyn-1,10-diyl)-bis-pyridine (1 mmol) 
and an equivalent of 1,8-diiodooctane Were mixed in aceto 
nitrile (1000 mL). The mixture Was re?uxed for 7 days. The 
solvent Was removed in vacuo after cooling and the resulting 
residue Was taken up in Water and partitioned betWeen diethyl 
ether and Water. The aqueous layer Was extracted extensively 
With diethyl ether to remove the starting materials. Most of 
the Water Was removed and the residue Was transferred into 
methanol. Methanol Was removed and dried under vacuum to 
afford the bis-pyridinium cyclophane (35% yield). HNMR 
(300 MHZ, D20) 10.30 (s, 2H), 9.37 (d, 1:57, 2H), 8.19 (d, 
1:81, 2H), 7.94 (dd, 1:81, 1:60, 2H), 4.95 (t, 1:84, 4H), 
2.49 (t, 1:66, 4H), 2.14-2.22 (m, 4H), 1.75-1.85 (m, 4H), 
1.61-1.68 (m, 8H), 1.54-1.58 (br, 8H), 1.49-4.58 (br, 4H). 
Example 4 
Preparation of Compound N,N'-(1,9-nonanediyl)-3, 
3'-(1,9-decanediyn-1,10-diyl)-bis-pyridinium dibro 
mide 
(CH2)6 
/ \ 
0% \@ T I / I /
N N 
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-continued 
3,3'-(1,9-Decanediyn-1,10-diyl)-bis-pyridine (1 mmol) 
and an equivalent of 1,9-dibromononane Were mixed in 
acetonitrile (1000 mL). The mixture Was re?uxed for 7 days. 
The solvent Was removed in vacuo after cooling and the 
resulting residue Was taken up in Water and partitioned 
betWeen diethyl ether and Water. The aqueous layer Was 
extracted extensively With diethyl ether remove the starting 
materials. Mo st of the Water Was removed and the residue Was 
transferred into methanol. Methanol Was removed and the 
product Was dried under vacuum to afford the bis-pyridinium 
cyclophane (38% yield) HNMR (300 MHZ, D20) 10.39 (s, 
2H), 9.52 (d, 1:57, 2H), 8.18 (d, 1:75, 8.00 (m, 2H), 5.06 (t, 
J:7.2, 4H), 2.49 (t, 1:63, 4H), 2.08-2.18 (br, 4H), 1.60-1.80 
(br, 12H), 1.42-1.56 (br, 8H), 1.37-1.40 (br, 2H). 
Example 5 
Preparation of Compound N,N'-(1,10-decanediyl)-3, 
3'-(1,9-decanediyn-1,10-diyl)-bis-pyridinium diio 
dide 
(CH2)6 
/ \ 
I \ / \ I \ _> 
/ / 
N N 
W
|@\ | @\ 
3,3'-(1,9-Decanediyn-1,10-diyl)-bis-pyridine (1 mmol) 
and an equivalent of 1,10-diiododecane Were mixed in aceto 
nitrile (1000 mL). The mixture Was re?uxed for 7 days. The 
solvent Was removed in vacuo after cooling and the resulting 
residue Was taken up in Water and partitioned betWeen diethyl 
ether and Water. The aqueous layer Was extracted extensively 
With diethyl ether remove the starting materials. Most of the 
Water Was removed and the residue Was transferred into 
methanol. Methanol Was removed and the product Was dried 
under vacuum to afford the bis-pyridinium cyclophane (40% 
yield). HNMR (300 MHZ, D20), 10.11 (s, 2H), 9.37 (d, 1:63, 
2H), 8.22 (dt, 1:78, 1:12, 2H), 8.03 (dd, 1:63, 1:78, 2H), 
4.99 (t, 1:81, 4H), 2.49 (t, 1:66, 4H), 2.15-2.17 (m, 4H), 
1.38-1.75 (m, 24H). CNMR, 147.73, 145.88, 142.71, 128.04, 
126.46, 102.54, 74.29, 61.82, 32.44, 28.71, 27.90, 27.83, 
27.40, 25.81, 20.21. 
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Example 6 
Preparation of Compound N,N'-(1,11-undecanediyl) 
3,3'-(1,9-decanediyn-1,10-diyl)-bis-pyridinium 
dibromide 
3,3'-(1,9-Decanediyn-1,10-diyl)-bis-pyridine (1 mmol) 
and an equivalent of 1,11-dibromoundecane Were mixed in 
acetonitrile (1000 mL). The mixture Was re?uxed for 7 days. 
The solvent Was removed in vacuo after cooling and the 
resulting residue Was taken up in Water and partitioned 
betWeen diethyl ether and Water. The aqueous layer Was 
extracted extensively With diethyl ether remove the starting 
materials. Mo st of the Water Was removed and the residue Was 
transferred into methanol. Methanol Was removed and the 
product Was dried under vacuum to afford the bis-pyridinium 
cyclophane (42% yield). HNMR (300 MHZ, D20), 9.92 (s, 
2H), 9.48 (d, 1:78, 2H), 8.22 (d, J:8.1, 2H), 8.05 (m, 2H), 
5.08 (br, 4H), 2.49 (t, 1:63, 4H), 2.05-2.15 (br, 4H), 1.70 
1.82 (br, 12H), 1.55-1.65 (br, 4H), 1.45-1.55 (br, 4H), 1.30 
1.45 (8H). 
Example 7 
Preparation of Compound 
1,12-bis-(pyridin-3 -yl)-dodecane 
/ 
N 
LDA (2M) (20.40 mL, 40.80 mmol) Was added drop-Wise 
to a solution of 3-picoline (3.80 g, 40.80 mmol) in THF (60 
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mL) at —780 C. The mixture Was stirred for 30 min and then 
1,10-dibromodecane (6.43 g, 16.32 mmol) in THF (10 mL) 
Was added drop-Wise. The resulting mixture Was Warmed to 
room temperature and stirred for 4 hrs. Fifty percent saturated 
NH4Cl Was added to the reaction mixture. The aqueous phase 
Was extracted With ethylacetate (2><40 mL), and the combined 
organic liquors Were Washed With 50% saturated brine (3x40 
mL) and saturated brine (40 mL), dried over anhydrous 
Na2SO4, and concentrated under reduced pres sure. The crude 
product Was puri?ed by column chromatography (hexanes: 
ethylacetate 2:1 to 1 :1) to afford 3 .98 g of the title compound. 
Yield: 75%. 1H NMR (300 MHZ, CDCl3) 6 1.17-1.40 (m, 
16H), 1.53-1.68 (m, 4H), 2.60 (t, 1:75 HZ, 4H), 7.20 (dd, 
J:7.8, 1.8 HZ, 2H), 7.48 (dt, J:7.8, 1.8 HZ, 2H), 8.43 (d, 1:51 
HZ, 2H), 8.44 (s, 2H) ppm; 13C NMR (75 MHZ, CDCl3) 6 
29.4, 29.7, 29.8, 29.9, 31.4, 33.3, 123.3, 135.8, 138.4, 147.2, 
150.0 ppm. 
Example 8 
Preparation of Compound N,N'-(1,4-butanediyl)-3, 
3'-(1,12-dodecanediyl)-bis-pyridinium diiodide 
3,3'-(Dodecan-1,12-diyl)-bis-pyridine (1 mmol) and an 
equivalent of 1,4-diiodobutane Were mixed in 4-methyl-2 
pentanol (265 mL). The mixture Was re?uxed for 28 days. The 
solvent Was removed in vacuo after cooling and the resulting 
residue Was taken up in methylene chloride and Water (50 mL, 
1:1). The methylene chloride layer containing the mono 
quatemary ammonium product Was removed and the remain 
ing aqueous layer further extracted With methylene chloride 
(3x25 mL). The Water layer containing the bis-pyridinium 
product Was evaporated under reduced pressure to loW vol 
ume (0.5 mL) and transferred into methanol (5 mL). The 
methanol Was removed and the product Was dried under 
vacuum to afford the bis-pyridinium cyclophane (3 5% yield). 
1H NMR (300 MHZ, CD3OD) 6 1.21-1.46 (m, 16H), 1.72 (m, 
4H), 2.18 (m, 4H), 2.56 (s, 6H), 2.81 (t, 1:75 HZ, 4H), 4.68 
(m, 4H), 8.28 (s, 2H), 8.79 (s, 2H), 8.83 (s, 2H) ppm; 13C 
NMR (75 MHZ, CD3OD) 6 18.8, 28.8, 28.9, 29.4, 29.6, 30.8, 
33.5, 61.7, 140.9, 142.3, 143.3, 144.9, 147.6 ppm. 
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Example 9 
Preparation of Compound 
12-(pyridin-3-yl)-1-bromododecane 
LDA (2 M) (10.5 mL, 21.22 mmol) Was added drop-Wise to 
a solution of3-picoline (2.17 g, 23.34 mmol) in THF (60 mL) 
at —78° C. The mixture Was stirred for 30 min and then 
1,1 1-dibromoundecane (10 g, 31.83 mmol) Was added in one 
portion. The resulting mixture Was Warmed to 0° C. and 
stirred for 4 hrs. Fifty percent saturated NH4Cl Was added to 
the reaction mixture. The aqueous phase Was extracted With 
ethylacetate (2><40 mL), and the combined organic liquors 
Were Washed With 50% saturated brine (3x40 mL) and satu 
rated brine (40 mL), dried over anhydrous Na2SO4, and con 
centrated under reduced pressure. The crude product Was 
puri?ed by column chromatography (hexanes:ethylacetate 
4:1) to afford 4.47 g 12-(pyridin-3-yl)-1-bromododecane. 
Yield: 59%. 
Example 10 
Preparation of Compound N,3'-(1,12-dodecanediyl) 
3,N'-(1, 12-dodecanediyl)-bis-pyridinium dibromide 
\ Br 
I / 
N 
I \ 
2/ ZBre /g I 
\ 
12-(Pyridin-3-yl)-1-bromododecane Was dissolved in 
acetonitrile (250 mL). The mixture Was re?uxed for 24 hours. 
The solvent Was removed in vacuo after cooling and the 
resulting residue Was taken up by Water and diethyl ether (50 
mL, 1: 1). The diethyl ether layer containing the starting mate 
rial Was removed and the remaining aqueous layer further 
extracted With diethyl ether (3x25 mL). The Water layer con 
taining the bis-pyridinium product Was evaporated under 
reduced pressure to loW volume (0.5 mL) and transferred into 
methanol (5 mL). The methanol Was removed and the product 
Was dried under vacuum to afford the bis-pyridinium cyclo 
phane (25% yield). 1H NMR (300 MHZ, DMSO-d6) 6 1.15 
1.39 (m, 32H), 1.63 (m, 4H), 1.90 (m, 4H), 2.78 (t, J:7.8 HZ, 
4H), 4.57 (t, J:7.2 HZ, 4H), 8.08 (dd, 1:81, 6.0 HZ, 2H), 8.48 
(d, J:8.1 HZ, 2H), 8.98 (d, 1:60 HZ, 2H), 9.10 (s, 2H) ppm; 
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13c NMR (75 MHZ, @3013) 6 25.5, 28.5, 28.8, 28.9, 29.0, 
29.9, 30.7, 31.7, 60.5, 127.4, 142.1, 142.8, 143.8, 144.9 ppm. 
Example 11 
Inhibition of [3H]nicotine and 
[3H]Methyllycaconitine Binding Assays 
Whole brain, excluding cortex and cerebellum, Was 
homogenized in 20 vol of ice-cold buffer, containing (in 
mM): 2 HEPES, 11.8 NaCl, 0.48 KCl, 0.25 CaCl2 and 0.12 
MgSO4, pH 7.5. Homogenate Was centrifuged (25,000 g, 15 
min, 40 C.). Pellets Were resuspended in 20 vol buffer and 
incubated at 37° C., for 10 min, cooled to 40 C. and centri 
fuged (25,000 g, 15 min, 4° C.). Pellets Were resuspended and 
centrifuged using the same conditions. Final pellets Were 
stored in assay buffer, containing (in mM): 20 HEPES, 118 
NaCl, 4.8 KCl, 2.5 CaCl2, and 1.2 MgSO4, pH 7.5 at —70° C. 
Upon use, ?nal pellets Were resuspended in ~20 vol assay 
buffer. Samples (250 pl) contained 100-140 pg of membrane 
protein, 3 nM [3H]nicotine or 3 nM [3H]methyllycaconitine 
(MLA), and bis-quatemary ammonium cyclophane analog 
(100 nM) in assay buffer containing 50 mM Tris. Control Was 
in the absence of analog. In [3H]nicotine and [3H]methylly 
caconitine binding assays, nonspeci?c binding Was deter 
mined in the presence of 10 pM cytisine and 10 pM nicotine, 
respectively. Incubations proceeded for 60 min at room tem 
perature using 96-Well plates and Were terminated by harvest 
ing on Uni?lter-96 GF/ B ?lterplates presoaked in 0.5% poly 
ethylenimine, using a Packard FilterMate harvester. After 
Washing 5 times With 350 pl ice-cold assay buffer, ?lter plates 
Were dried (60 min, 4° C.), bottom-sealed, and ?lled With 
Packard’s MicroScint 20 cocktail (40 pl/Well). After 60 min, 
?lter plates Were top-sealed, and radioactivity determined 
using a Packard TopCount. Protein concentrations Were 
determined using the Bradford dye-binding procedure bovine 
serum albumin as the standard. The results are summarized in 
Table 1. 
Example 12 
Inhibition of Nicotine-evoked [3H]Neurotransmitter 
Release Assay 
Rat striatal slices (500 pm thickness, 6-8 mg Wet Weight) 
Were incubated for 30 minutes in Krebs buffer (118 mM 
NaCl, 4.7 mM KCl, 1.2 mM MgCl2, 1.0 mM NaH2PO4, 1.3 
mM CaCl2, 11.1 mM glucose, 25 mM NaHCO3, 0.11 mM 
L-ascorbic acid, and 0.004 mM disodium EDTA; pH 7.4, and 
saturated With 95% 02/ 5% CO2) in a metabolic shaker at 34° 
C. Slices Were rinsed With 15 mL of fresh buffer and incu 
bated for an additional 30 minutes in fresh buffer containing 
0.1 pM [3 H] dopamine (DA; 6 slices/3 mL). Subsequently, 
slices Were rinsed With 15 mL of fresh buffer and transferred 
to a glass superfusion chamber. Slices Were superfused (1.0 
mL/min) for 60 minutes With Krebs buffer containing 
nomifensine (10 pM) and pargyline (10 pM) and maintained 
at 34° C., pH 7.4, With continual aeration (95% O2/5% CO2). 
TWo ?ve minute samples (5 mL each) Were collected to deter 
mine basal out?oW of [3H]DA. The bis-quatemary ammo 
nium cyclophane analogs Were added to the superfusion 
buffer after the collection of the second sample and remained 
in the buffer until 12 consecutive ?ve minute samples Were 
collected. Subsequently, S-(—)-nicotine (10 pM) Was added to 
the buffer and an additional 12 consecutive ?ve minute 
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samples Were collected. At the end of the experiment, each 
slice Was solubiliZed and the [3 H] content of the tissue deter 
mined. 
Radioactivity in the superfusate and tissue samples Was 
determined by liquid scintillation spectroscopy. Fractional 
release for tritium collected in each sample Was divided by the 
total tritium present in the tissue at the time of sample collec 
tion and Was expressed as a percentage of total tritium. Basal 
[3H]out?oW Was calculated from the average of the tritium 
collected in the tWo ?ve minute samples just before addition 
of the quaternary ammonium analog. The sum of the increase 
in collected tritium resulting from either exposure to the test 
compound or exposure to S-(—)-nicotine in the absence and 
presence of the test compound equaled total [3H]over?oW. 
[3 H] Over?ow Was calculated by subtracting the [3 H] out?oW 
during an equivalent period of prestimulation from the values 
in samples collected during and after drug exposure. Inas 
much as the radiolabelled compounds Were not separated and 
identi?ed, the tritium collected in superfusate is referred to as 
either [3H]out?oW or [3H]over?oW, rather than as [3H]DA. 
[3 H] Over?ow primarily represents [3H]DA in the presence of 20 
nomifensine and pargyline in the superfusion buffer. 
The bis-quaternary ammonium cyclophane analogs Were 
evaluated for their ability to evoke [3H]DA release from rat 
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striatal slices. In addition, the classical competitive nicotinic 
antagonist DHBE Was also examined in this assay for com 
parison. None of the compounds examined had any signi? 
cant [3H]DA releasing properties in this assay in the concen 
tration range tested. 
The bis-quaternary ammonium cyclophane analogs Were 
also evaluated for their ability to inhibit nicotine evoked [3 H] 
DA release. In these experiments, the striatal slices Were 
superfused for 60 minutes With 100 nM concentration of the 
bis-quaternary ammonium cyclophane analogs prior to nico 
tine (l0 uM) exposure. Antagonist activity Was evaluated by 
comparing the nicotine evoked [3H]over?oW in the absence 
and presence of the analogs. The relative order of potency of 
the bis-quaternary ammonium cyclophane analogs for inhi 
bition of nicotine-evoked [3H]DA release from rat striatal 
slices is illustrated in Table 1. 
Table l. Bis-Quaternary Ammonium Cyclophane Com 
pounds: Af?nity for the BBB Choline Transporter, Inhibition 
of [3H]Nicotine and [3H]Methyllycaconitine (MLA) Binding 
to Rat Striatal Nicotinic Receptors and Inhibition of Nicotine 
evoked [3H]Dopamine Release from Superfused Rat Striatal 
Slices 
Inhibition of 
A?'lnity for the Nicotine 
BBB choline Inhibition of Inhibition of evoked 
transporter Ki [3H]Nicotine [3H]MLA [3H]DA 
COMPOUND (pM) binding“ Bindingl7 releaseC 
33.6 7% 2% ND 
Example 2 
ND 9% 0% ND 
1.4 0% 3% ND 
Example 4 
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-continued 
Inhibition of 
Af?nity for the Nicotine 
BBB choline Inhibition of Inhibition of evoked 
LI‘aHSpOI‘tcl‘ Ki [3H]Nicotine [3H]MLA [3H]DA 
COMPOUND (pM) binding“ Bindingl7 releaseC 
0.8 0.55 (Ki, uM) 4.64 (Ki, uM) 19% 
2I 
N 9 N 
/® I /® I 
\ \ / \ 
Example 5 
15 .2 11% 3% ND 
K—\ ND 14 r 2.6% 3.0 r 3.0% 23% 
N N 
@\ 21 @\ 
l e l 
/ / 
Example 8 
\ NDd 2% 0% 20% 
@/ 9 N 
N ZBI \ 
Example 10 
Tata are % inhibition at 100 nM concentration of the bis-quaternary ammonium cyclophane analogs for at least l-3 independent experiments; With the exception of When 
a Ki value in M is provided, in Which case a full concentration effect Was evaluated. Speci?c binding in the [3H]nicotine binding assay is calculated as the difference 
betWeen the total binding of3 nM [3H]nicotine and nonspeci?c binding in the presence of 10 M cold cytisine. 
bSpeci?c binding for the [3H]MLA binding assay is calculated as the difference betWeen the total binding of2.5 nM [3H]MLA to the receptors alone and its nonspeci?c 
binding in the presence ofl uM cold nicotine. 
CAnalog-induced inhibition ofnicotine-evoked [3H]DA release is calculated as a percent ofthat in the absence ofbis-quaternary ammonium cyclophane analog. 
dND indicates not determined. 
It Will be appreciated that, although speci?c embodiments 60 We claim: 
of the invention have been described herein for purposes of 1- A Compound of Formula (I) 
illustration, various modi?cations may be made Without (I) 
departing from the spirit and scope of the invention. All such /Q\ 
modi?cations and variations are intended to be included 65 X199 Rl\ /R2@ 9X2 
herein Within the scope of this disclosure and the present T 
invention and protected by the following claims. 
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wherein 
X16 and X26 are each independently an organic or inor 
ganic anion; 
Q and T are each independently attached to R1 and R2; 
Q is alkyl; 
T is alkynyl; 
R1 and R2 are each six membered rings as shoWn in formula 
(HA); 
10 
(HA) 
R14 R12 
R4 ‘l? R — 10 
\ / 15 
R6 R8 
R8 or R12 is replaced by one attachment to T in R1 and R2; 
R4 is replaced by one attachment to Q in R1 and R2; 
R6, R8, R10, R12, and R14, When present, are each indepen 
dently selected from the group consisting of hydrogen, 
loWer alkyl, halo, cyano, nitro, tri?uoromethyl, 
hydroxymethyl, hydroxyethyl and hydroxypropyl. 
2. The compound of claim 1, Wherein Q is i(CH2)4i, 
*(CH2)6< *(CH2)8< *(CH2)9< *(CH2)1O*, 
i(CH2)1 1* or i(CH2)1 2i; and T is 4CECi(CH2)6i 
CECi. 
20 
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3. The compound of claim 2, Wherein 
X16 and X26 are bromide or iodide. 
4. The compound of claim 1 selected from the group con 
sisting of: 
N,N'-(l ,6-hexanediyl)-3,3'-(l,9-decanediyn- l , l0-diyl) 
bis-pyridinium diiodide; 
N,N'-(l ,8-octananediyl)-3,3'-(l ,9-decanediyn-l , l 0-diyl) 
bis-pyridinium diiodide; 
N,N'-(l ,9-nonanediyl)-3,3'-(l ,9-decanediyn-l , l 0-diyl) 
bis-pyridinium dibromide; 
N,N'-(l , l O-decanediyl) -3 ,3'-( l , 9-decanediyn- l , l 0-diyl) 
bis-pyridinium diiodide; and 
N,N'-(l ,l l'-undecanediyl)-3,3'-(l ,9-decanediyn-l ,10 
diyl)-bis-pyridinium dibromide. 
5. A composition comprising a pharmaceutically accept 
able carrier and a compound of claim 1. 
6. A composition comprising a pharmaceutically accept 
able carrier and a compound of claim 2. 
7. A composition comprising a pharmaceutically accept 
able carrier and a compound of claim 3. 
8. A composition comprising a pharmaceutically accept 
able carrier and a compound of claim 4. 
9. N,N'-(l ,4-butanediyl)-3,3'-(l , l 2-dodecanediyl)-bis-py 
ridinium diiodide. 
